Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 11.85 on Friday. The company’s market cap is $548.95 million. The firm has a 50-day moving average price of $11.31 and a 200-day moving average price of $10.68. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter in the previous year, the business earned $0.24 earnings per share. The company’s revenue was up 15.3% on a year-over-year basis. Equities research analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://ledgergazette.com/2017/09/22/sachiko-kuno-sells-1000000-shares-of-sucampo-pharmaceuticals-inc-scmp-stock.html.
Several hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Sucampo Pharmaceuticals in the second quarter worth $132,000. Public Employees Retirement System of Ohio raised its stake in shares of Sucampo Pharmaceuticals by 37.7% in the second quarter. Public Employees Retirement System of Ohio now owns 46,222 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 12,663 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Sucampo Pharmaceuticals by 4.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 790 shares during the last quarter. State Street Corp raised its stake in shares of Sucampo Pharmaceuticals by 7.3% in the second quarter. State Street Corp now owns 599,420 shares of the biopharmaceutical company’s stock worth $6,290,000 after purchasing an additional 40,929 shares during the last quarter. Finally, Dana Investment Advisors Inc. raised its stake in shares of Sucampo Pharmaceuticals by 17.0% in the second quarter. Dana Investment Advisors Inc. now owns 187,449 shares of the biopharmaceutical company’s stock worth $1,968,000 after purchasing an additional 27,294 shares during the last quarter. Hedge funds and other institutional investors own 55.44% of the company’s stock.
Several brokerages recently issued reports on SCMP. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Leerink Swann began coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They set an “outperform” rating and a $15.00 price target for the company. Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, ValuEngine downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $17.63.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.